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Abstract
Background: The development of plasma biomarkers could facilitate early detection, risk assessment and therapeutic
monitoring in Alzheimer’s disease (AD). Alterations in ceramides and sphingomyelins have been postulated to play a role in
amyloidogensis and inflammatory stress related neuronal apoptosis; however few studies have conducted a comprehensive
analysis of the sphingolipidome in AD plasma using analytical platforms with accuracy, sensitivity and reproducibility.
Methods and Findings: We prospectively analyzed plasma from 26 AD patients (mean MMSE 21) and 26 cognitively normal
controls in a non-targeted approach using multi-dimensional mass spectrometry-based shotgun lipidomics [1,2] to
determine the levels of over 800 molecular species of lipids. These data were then correlated with diagnosis, apolipoprotein
E4 genotype and cognitive performance. Plasma levels of species of sphingolipids were significantly altered in AD. Of the 33
sphingomyelin species tested, 8 molecular species, particularly those containing long aliphatic chains such as 22 and 24
carbon atoms, were significantly lower (p,0.05) in AD compared to controls. Levels of 2 ceramide species (N16:0 and N21:0)
were significantly higher in AD (p,0.05) with a similar, but weaker, trend for 5 other species. Ratios of ceramide to
sphingomyelin species containing identical fatty acyl chains differed significantly between AD patients and controls. MMSE
scores were correlated with altered mass levels of both N20:2 SM and OH-N25:0 ceramides (p,0.004) though lipid
abnormalities were observed in mild and moderate AD. Within AD subjects, there were also genotype specific differences.
Conclusions: In this prospective study, we used a sensitive multimodality platform to identify and characterize an essentially
uniform but opposite pattern of disruption in sphingomyelin and ceramide mass levels in AD plasma. Given the role of brain
sphingolipids in neuronal function, our findings provide new insights into the AD sphingolipidome and the potential use of
metabolomic signatures as peripheral biomarkers.
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Introduction
As the world population ages, the number of older adults
developing dementia is estimated to quadruple by mid-century to
over 106 million worldwide [3]. Alzheimer’s disease (AD) is the
most common dementia among all the clinically-recognized
dementias in the aging population [4,5]. Although the cause is
not known, there are profound biochemical alterations in multiple
pathways in the AD brain including changes in amyloid-beta
protein metabolism, tau phosphorylation, membrane lipid dysreg-
ulation and synaptic neurotransmission. Recent pathological,
biochemical, and genetic studies have led to major insights into
AD pathogenesis [6]. Among the encouraging observations are
links made between cardiovascular risk conditions, lipid metabo-
lism, and the development of AD [7]. Further, the apolipoprotein
E4 (ApoE4) genotype, a major determinant of risk for sporadic
AD, is a component of lipoproteins in plasma and brain and may
lie at the crossroads between the lipidome and dementia [8].
These insights suggest that treatments aimed at reducing risk
conditions may hold promise to delay the onset of AD dementia,
slow the progression, and possibly prevent AD altogether. Since
disease modifying drugs are likely to be most effective early in the
disease course, the discovery of highly sensitive biomarker(s) for
the early diagnosis of AD (at mild or even preclinical stages) is
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21643extremely important. Currently, the sensitivity and specificity of
the clinical diagnosis of AD is quite low (approximately 80%; [9])
and the currently available central AD biomarkers (MRI
volumetrics, FDG-PET, CSF assays) perform at similar accuracy
levels [10,11]. Moreover, effective biomarkers are also very useful
in assessing disease progression or response to treatment. The
cellular lipidome, consisting of hundreds of thousands of lipid
species, represents a rich source of biomarkers for the early
diagnosis of AD.
Metabolomics tools enable us to study the metabolome, the
repertoire of small molecules present in cells and tissue
[12,13,14]. The identities, concentrations, and fluxes of these
substances are the final product of interactions between gene
expression, protein expression, and the cellular environment.
Metabolomics tools have been used to characterize metabolic
signatures for several diseases including depression [15,16,17],
motor neuron disease [18], Parkinson’s disease [19], cocaine and
opiate addiction [20,21], schizophrenia [22,23,24], and Alzhei-
mer’s Disease [25]. As stated previously, there is now extensive
preclinical and in-vitro literature documenting a relationship
between altered lipid metabolism and amyloidogenesis, oxidative
stress and apoptosis [26]. Previous studies with post-mortem
brain tissue samples have demonstrated altered lipidomes at the
different stage of AD pathogenesis (reviewed in [27]. For
example, multiple classes of sphingolipids are altered not only
at the late stage of the disease [28], but also at the earliest
clinically recognizable stage of AD [29,30]. All major classes of
phospholipids are ubiquitously decreased at the late stage of AD
[31]. Among these, the levels of plasmalogen (a major component
in nerve tissue membranes counting for up to 85% of
ethanolamine glycerophospholipid, or ,30% of total phospho-
lipids of these membranes) are gradually reduced as progress of
AD severity [32]. It is conceivable that these changes could lead
to or be parallel with the changes of either the content or the
composition or both of the lipid species in plasma of AD patients.
There are many obvious advantages to a peripheral plasma
marker (over central markers) in terms of cost, risks and ability to
monitor individuals over time. A very recent study has shown a
promising relationship between altered plasma ceramide levels
and hippocampal volume loss in mild cognitive impairment
supporting the hypothesis that disruptions in ceramide metabo-
lism may be linked to early neurodegenerative and pathologic
changes [33]. However, the lack of sensitive and efficient ‘‘mega’’
lipid biochemistry platforms has limited the ability to simulta-
neously study the dozens of different pathways that may be
affected in AD in relation to clinical phenotype and genotype.
Shotgun lipidomics studies the pathways and networks of
cellular lipids in biological systems on a large scale. It involves the
identification and quantitation of hundreds of cellular lipid
molecular species as well as their interactions with other species.
Multi-dimensional mass spectrometry-based shotgun lipidomics
(MDMS-SL) is one of the leading analytic platforms in current
lipidomics practices due to its high accuracy, efficiency, sensitivity,
and reproducibility [1,2]. In this study, we used a non-targeted
MDMS-SL approach to measure the levels of over 800 molecular
species of choline glycerophospholipid (PC), lysoPC (LPC),
ethanolamine glycerophospholipid (PE), phosphatidylinositol,
sphingomyelin (SM), ceramide, and triacylglycerol (TAG) in the
plasma of AD individuals and cognitively normal controls. The
main goals of the study were to examine the hypothesis that the
plasma lipidome is altered in early AD, and secondary goals were
to characterize lipid changes that might be differentially related to
cognitive status or genotype as well as to identify potential lipid
pathways that might be disrupted in AD.
Materials and Methods
Materials
Synthetic phospholipids including 1,2-dimyristoleoyl-sn-glycero-
3-phosphocholine (14:1-14:1 PC), 1,2-dipalmitoleoyl-sn-glycero-3-
phosphoethanolamine (16:1-16:1 PE), 1,2-dipentadecanoyl-sn-
glycero-3-phosphoglycerol (15:0-15:0 PG), 1-myristoyl-2-hydrox-
yl-sn-glycero-3-phosphocholine (14:0 LPC), N-lauroyl sphingomy-
elin (N12:0 SM), and N-heptadecanoyl ceramide (N17:0 ceramide)
were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL,
USA). Note that the prefix ‘‘N’’ denote the amide linkage of the
fatty acyl chain. Triheptadecenoylglycerol (T17:1 TAG) was
purchased from Nu-Chek Prep, Inc. (Elysian, MN, USA).
Deuterated cholesterol was purchased from Cambridge Isotope
Laboratories, Inc. (Cambridge, MA, USA). All the solvents were
obtained from Burdick and Jackson (Honeywell International Inc.,
Burdick and Jackson, Muskegon, MI, USA). All other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Subjects
AD (n=26) and elderly control subjects (n=26) were recruited
prospectively from the Joseph and Kathleen Bryan Alzheimer’s
Disease Research Center (Bryan ADRC) and the Department of
Psychiatry, both at Duke University. Patients included in the study
had diagnoses of Probable AD (NINDS) using current criteria
following history and informant interview, complete neurological
examination, cognitive screening and securing standard blood
chemistries, imaging, and laboratory studies. The Mini-Mental
State examination (MMSE), a brief screening tool of cognitive
status was used to categorize AD patients as mild or moderate,
consistent with routine clinical practice. Normal controls were
participants who were determined to be free of dementia as well as
other significant neuropsychiatric disorders after reviewing their
medical history, informant interviews, functional status and
neuropsychological performance as well as ratings of mood and
clinical examinations. Our entry criteria excluded subjects with
current major depression or substance abuse, subjects with other
neurologic disorders such as Parkinson’s disease or stroke, and
those who were unwilling or unable to perform cognitive testing.
Of the 26 AD subjects, 17 had mild AD (MMSE$20) and others
Table 1. Clinical and demographic characteristics of
Alzheimer’s subjects and controls
a.
Control AD P Test
n2 6 2 6
Age Range 57–87 61–89
Age, Mean (SD) 73.0 (7.7) 77.2 (6.5) 0.074 WT
% Male 42 46 1 FET
Years Education, Mean (SD) 16.0 (2.6) 14.4 (2.8) 0.062 WT
MMSE, Median (MAD) 29.0 (1.5) 21.0 (3.7) 2.50E-09 WT
Logical Memory I, Median (MAD) 17.0 (4.4) 2.0 (1.5) 1.00E-09 WT
Logical Memory II, Median (MAD) 15.5 (3.7) 0.0 (0.0) 5.10E-10 WT
% Using Statins 27 42 0.38 FET
% with APOE4 Genotype 25% 67% - -
aWT, Wilcoxon rank-sum test, two-sided; FET, Fisher’s exact test, two-sided; SD,
standard deviation; MAD, median absolute deviation; MMSE, Mini-Mental State
Examination.
doi:10.1371/journal.pone.0021643.t001
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subjects appear in Table 1.
Ethics statement
All normal control subjects and AD patients provided informed
consent prior to collection of any data. For AD patients, informed
consent was also obtained from their legally authorized represen-
tative/family member if deemed appropriate. This research was
approved by the Duke University Medical Center institutional
review board and was conducted according to the principles
expressed in the Declaration of Helsinki.
Lipid sample preparation from human plasma
Fasting samples were collected and cold stored using a
standardized procedure. After fasting overnight, a 10 mL
K3EDTA tube of blood was collected via venipuncture. The
blood was mixed by gentle inversion 8–10 times and placed on ice
until centrifuged for 30 minutes at 3500 rpm’s at 4uC. After
centrifuging, plasma was aliquoted and then frozen at 280uC. All
samples were run blinded. A protein assay on each plasma sample
was performed by using BCA method with bovine albumin as
standard. After 200 ml of plasma from each plasma sample was
transferred to a disposable culture borosilicate glass tube
(166100 mm), a premixed lipid solution used as internal standards
for quantification of lipid species was added to each plasma sample
based on its protein concentration. These internal standards
include 15:0-15:0 PG (150 pmol/mg protein), 16:1-16:1 PE
(15 pmol/mg protein), 14:1-14:1 PC (2000 pmol/mg protein),
T17:1 TAG (3000 pmol/mg protein), 14:0 LPC (1000 pmol/mg
protein), N12:0 SM (500 pmol/mg protein), N17:0 ceramide
(15 pmol/mg protein), and others. Addition of these internal
standards allows the final quantified lipid content to be normalized
to both the protein content and/or the plasma sample volume and
allows the elimination of a potential loss from the incomplete
recovery. These internal standards have been selected because
they only represent %0.1% of the endogenous cellular lipid mass
as demonstrated by ESI/MS lipid analysis.
Lipid extracts were prepared by using a modified procedure of
Bligh and Dyer as previously described [34] and each was
resuspended in 500 ml of dichloromethane/methanol (1:1, v/v)
which corresponded to a concentration of 3 nmol/ml. A portion of
each individual lipid extract (approximately 100 ml) was treated
with LiOMe and followed by being washed with hexane as
previously described [35]. The treated lipid samples were used for
Figure 1. Representative tandem mass spectrometric analyses of lipid classes present in a human plasma lipid extract. Lipid samples
were prepared and mass spectrometric analysis of individual sample was performed as described in ‘‘Material and Methods’’ in details. Panel A shows
a mass spectrum of NLS183 (corresponding to the neutral loss of phosphocholine) displaying the presence of PC and SM species in the hexane-
washed lipid solution; the spectrum was acquired in the positive-ion mode after addition of a small amount of LiOH to the lipid solution. Panel B
shows a mass spectrum of NLS213 (corresponding to the neutral loss of phosphocholine plus methyl aldehyde) displaying the presence of SM species
in the LiOMe-treated lipid solution; the spectrum was acquired in the positive-ion mode after addition of a small amount of LiOH to the lipid solution.
Panel C shows a mass spectrum of NLS222 (corresponding to the neutral loss of Fmoc) displaying the presence of PE species in the hexane-washed
lipid solution; the spectrum was acquired in the negative-ion mode after in situ addition of Fmoc-Cl to the lipid solution. Panel D shows a mass
spectrum of NLS256 (corresponding to the neutral loss of 2-palmitoleyl aldehyde and a water molecule) displaying the presence of ceramide species
in the LiOMe-treated lipid solution; the spectrum was acquired in the negative-ion mode after addition of a small amount of LiOH to the lipid
solution. IS denotes internal standard; NLS stands for neutral loss scan.
doi:10.1371/journal.pone.0021643.g001
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sample. Another portion of each individual original lipid extract
was washed with 2 ml of hexane for twice to remove most of the
non-polar lipids such as TAG, cholesterol, and cholesterol esters
which are very abundant in plasma lipid extracts and interfere
with the quantification of phospholipid classes. The residue lipid
Figure 2. Representative 2D MS analyses of TAG species in a human plasma lipid extract. Neutral loss scans (NLS) of all naturally-
occurring aliphatic chains (i.e. the building blocks of TAGs) of a human plasma lipid extract were used to determine the identities of each lithiated
molecular ion, deconvolute isomeric species, and quantify individual TAG species by comparisons with a selected internal standard (i.e., T17:1 TAG,
shown in NLS268). Collision activation was performed with collision energy of 32 eV and gas pressure of 1 mT on a triple quadrupole mass
spectrometer (TSQ Quantum Ultra Plus, Thermo Fisher Scientific, San Jose, CA, USA). All displayed mass spectral traces are normalized to the base
peak in each trace.
doi:10.1371/journal.pone.0021643.g002
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using intrasource separation followed by employing multi-
dimensional mass spectrometric analysis.
Lipidomic analysis of human plasma lipid extracts by
multi-dimensional mass spectrometry-based shotgun
lipidomics (MDMS-SL)
A triple-quadrupole mass spectrometer (Thermo Fisher TSQ
Vantage, San Jose, CA, USA) equipped with an automated
nanospray apparatus (i.e., Nanomate HD, Advion Bioscience Ltd.,
Ithaca, NY) and Xcalibur system software were utilized in the
study as previously described [36]. Each originally-prepared lipid
extract was diluted to ,50 pmol/ml with dichloromethane/
methanol/isopropanol (1:2:4, v/v/v) prior to infusion to the mass
spectrometer for the analyses of neutral lipids including TAG,
cholesterol, and cholesterol esters. Each lipid solution prepared
after treatment with LiOMe or after washing with hexane was also
properly diluted prior to infusion to the mass spectrometer for the
analyses of sphingolipids or phospholipids, respectively. Proper
dilution of the lipid solution is crucial for quantification to
guarantee no lipid aggregation is formed during analysis and
minimizing any effects of residual inorganic components carried
over during lipid extraction on ion suppression and/or chemical
noise. The diluted lipid extract was directly infused through the
nanomate device. Typically, a 1-min period of signal averaging in
the profile mode was employed for each survey scan. For tandem
mass spectrometry, a collision gas pressure was set at 1.0 mTorr
but the collision energy was varied with the classes of lipids as
described previously [2]. Typically, a 2 to 5-min period of signal
averaging in the profile mode was employed for acquisition of each
tandem MS spectrum. All the MS spectra and tandem MS spectra
were automatically acquired by a customized sequence subroutine
operated under Xcalibur software.
Mass spectra in survey scanning mode were acquired after
intrasource separation of each prepared and properly diluted lipid
solution as previously described [37,38]. TAG species were
Table 2. Lipid classes, species and their mass levels in
Alzheimer and control subjects
a.
Lipid Class # of Species
Control
Mean ± SD
AD
Mean ± SD P
PC 65 30692 5 65.1 0.022
PE 86 1.6660.54 1.5360.52 0.41
PI 25 0.5160.15 0.4460.15 0.11
SM 33 9.3563.78 7.3362.38 0.026
LPC 14 2.5760.70 2.4160.59 0.39
Ceramide 29 0.2160.08 0.2360.07 0.26
Free.Chol. 1 1666.2 1666 0.85
Chol.Ester NA 32613 32613 0.96
TAG .500 11.665.5 13.566.0 0.24
aSD denotes standard deviation. P values were computed by Welch two-sample
t-test. All the results are obtained by shotgun lipidomics as described under
Materials and Methods and presented in unit of nmol/mg protein. See text for
abbreviations.
doi:10.1371/journal.pone.0021643.t002
Figure 3. Mass levels of N22:1 (panel A) and N24:1 (panel B)
sphingomyelin species in AD and healthy controls.
doi:10.1371/journal.pone.0021643.g003
Table 3. Sphingomyelin species significantly different
between AD and control groups
a.
Sphingomyelin Species P-value Q-value
N22:1 0.006 0.146
N20:0 0.012 0.146
N22:0 0.014 0.146
N23:0 0.020 0.146
N23:1 0.025 0.146
N24:1 0.029 0.146
N21:0 0.034 0.146
N24:0 0.035 0.146
N17:1 0.073 0.192
N24:2 0.077 0.192
N18:0 0.084 0.192
aas determined by Wilcoxon rank sum tests at a p-level of ,0.1.
Q values are cumulative false discovery rates estimated by the R qvalue
package.
doi:10.1371/journal.pone.0021643.t003
Lipidomics in Alzheimer’s Disease
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solution as described in detail [39]. Cholesterol and cholesterol
esters were quantified directly from the originally-prepared lipid
solution as previously described [40]. Ceramide and SM species
were identified and quantified directly from lipid solutions after
treatment with LiOMe or hexane washing [41,42]. PC and LPC
species were identified and quantified directly from lipid solution
after washing with hexane as described [42]. PE and PI species
were identified and quantified directly from lipid solution with
hexane washing as previously described in detail [2,43]). In
summary, each individual lipid species corresponding to each of
the ion peaks was identified using multi-dimensional mass
spectrometry through building block analyses [2]. The identified
species were quantified using a two-step approach as previously
described [2]. First, the abundant and non-overlapping molecular
species of a class shown in one of the survey scans was quantified
by comparison with a pre-selected internal standard of the class
after
13C de-isotoping. Next, some or all of the determined
molecular species of the class (plus the pre-selected internal
standard) were used as standards to determine the mass content of
other low-abundance or overlapping molecular species using one
or multiple tandem mass traces (each of which represents a specific
building block of the class of interest) by two-dimensional MS.
APOE Genotyping
APOE genotypes were determined using TaqMan-based allelic
discrimination assay (Applied Biosystems). Specifically, APOE
status was established using two separate genotypes: (1) rs429358
334 T/C (ABI assay ID: C_3084793_20), and (2) rs7412 472T/C
(ABI assay ID: C_904973_10). Assays were conducted per
manufacturer’s protocol, using 10 ng of DNA from each subject
per assay. Fluorescence outputs were quantified in real time using
a 7900HT Fast Real Time PCR System and the data will be
analyzed using SDS software v.2.2.2 (Applied Biosystems). APOE
Figure 4. Mass levels of N16:0 (panel A) and N21:0 (panel B)
ceramide species in AD and healthy controls.
doi:10.1371/journal.pone.0021643.g004
Table 4. Ceramide species significantly different between AD
and control groups
a.
Ceramide Species P-value Q-value
N21:0 0.027 0.146
N16:0 0.030 0.146
N26:0 0.058 0.192
OH-N24:2 0.063 0.192
OH-N24:1 0.077 0.192
N28:2 0.078 0.192
N23:0 0.081 0.192
aas determined by Wilcoxon rank sum tests at a p-level of ,0.1.
Q values are cumulative false discovery rates estimated by the R qvalue
package.
doi:10.1371/journal.pone.0021643.t004
Table 5. Ratios of ceramides to sphingomyelins with same
fatty acid chain show multiple significant differences between
Alzheimer’s patients and controls
a.
Fatty Acid Chain
Control
Mean ± SD
AD
Mean ± SD P
N22:0 0.02860.013 0.04760.027 0.00094*
N23:0 0.08560.046 0.13960.071 0.002*
N16:0 0.00160.001 0.00160.001 0.00214*
N21:0 0.00160.001 0.00460.005 0.00595
N24:1 0.02760.013 0.04260.026 0.00785
N24:0 0.35260.167 0.54460.359 0.01367
N24:2 0.00360.002 0.00560.005 0.0218
N18:1 0.0000560.00015 0.0004160.002 0.31139
N15:0 0.000160.001 060 0.33628
N22:1 0.0003660.00049 0.00160.001 0.45193
N23:1 0.00160.002 0.00160.002 0.62063
N19:0 0.00560.019 0.00160.002 0.63989
N22:2 0.00260.006 0.00160.002 0.77069
aP values were computed by Wilcoxon rank sum test, two sided.
*denotes significance at a Bonferroni corrected alpha of 0.0038.
doi:10.1371/journal.pone.0021643.t005
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APOE genotype data was only available for 49 subjects (34
controls and 15 AD, See Table 1).
Statistical Analysis
We performed statistical analyses using the R statistical
programming system [44] (http://www.R-project.org). We treated
the variables MMSE, Logical Memory I, and Logical Memory II
as ordered categorical variables, and therefore, rather than
reporting means and standard deviations, we report medians
and median absolute deviations (R function ‘mad’, defined as
1.4826 times the median of the absolute value of the deviation
from the median). We used two-sided Wilcoxon rank sum tests for
differences in location for these variables as well as for age and
years of education. We used two-sided Fisher’s exact tests for
independence of affection status from each of (a) the number of
males, (b) the number of subjects using statins, and (c) the number
of subjects with at least one APOE e4 allele. For tests of differences
between two independent groups, we used Wilcoxon rank sum
tests to compute p-values, as the underlying variables are not in
general normally distributed. We calculated Q values (cumulative
false discovery rates) using the R ‘qvalue’ package [45]. We used
two-sided Wilcoxon signed rank tests of the null hypothesis that
the distribution of differences in standardized means is symmetric
around 0 (R function ‘wilcox.test’).
Results
Shotgun lipidomics analysis of plasma samples
We analyzed 9 lipid classes in the study including choline
glycerophospholipid (PC), lysoPC (LPC), ethanolamine glycero-
phospholipid (PE), phosphatidylinositol, sphingomyelin (SM),
ceramide, triacylglycerol (TAG), cholesterol and cholesterol esters
by multi-dimensional mass spectrometry-based shotgun lipidomics
[1,2]. This platform has previously employed for quantitative
analysis of lipidomes (e.g., brain tissues and cerebrospinal fluid)
from AD patients [29,46]. A few representative tandem MS
spectra for identification and second step quantification of PC, PE,
SM, and ceramide species were shown in Figure 1. A two
dimensional mass spectrum for identification and quantitation of
TAG species was also illustrated (Figure 2). For example, the
primary ion at m/z 837.7 was crossed with the 14:0, 16:0, 16:1,
18:0, 18:1, and 18:2 fatty acyl building blocks (see the broken line
in Figure 2). A lithiated triacylglycerol species at m/z 837.7 must
contain 53 total carbon atoms with 2 double bonds or 54 total
carbon atoms with 9 double bonds, and the ion intensities resulting
from the neutral loss of the three acyl chains from a given TAG
molecule are nearly equal [39]. Thus, isomeric TAG species of
14:0-18:1-18:1, 14:0-18:0-18:2, 16:0-16:0-18:2, and 16:0-16:1-
18:1 were identified. Other TAG species corresponding to other
primary ions were identified similarly. The numbers of molecular
species and the total masses of each individual lipid class were
Figure 5. Ratios of specific ceramides to the sphingomyelins with the same fatty acid chains. See Table 5 for P values.
doi:10.1371/journal.pone.0021643.g005
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species present in human plasma lipid extracts with mass levels of
3069 and 2565 nmol/mg protein (i.e., 18906567 and
15756315 nmol/ml) in control and AD individuals, respectively
(p=0.022). These results are well comparable with those
determined by LC-MS, which determined a total mass of
1974 nmol/ml from 31 PC species [47]. In exploratory analyses,
the mass levels of total PC and SM were lower in AD patients in
comparison to the control group (Table 2). Since we determined
over 800 molecular species and covered the categories of
(phospho)glycerolipids, sphingolipids, and sterols in the study, it
is very difficult to process the dataset and make a simple
comparison. Accordingly, in the current report, we mainly focused
on the detailed analyses of sphingolipids at the level of individual
molecular species.
Mass levels of sphingomyelin species in AD patients
Wilcoxon rank sum tests revealed significant differences in the
quantified sphingomyelin species between the AD and control
groups. Of the 33 SM species tested, we found that 8 SM
molecular species, particularly those containing long aliphatic
chains such as 22 and 24 carbon atoms, were significantly lower
(p,0.05) in AD patients as compared to the age-matched
cognitively normal controls (Table 3). For example, Figure 3A
displays the distribution of the mass levels of SM species N22:1 in
the AD and control groups and Figure 3B shows the mass
Figure 6. Rank of the changed mean mass levels of individual sphingomyelin and ceramide molecular species in all AD patients
relative to the normal controls (panel A) and the differences in sphingomyelins and ceramides between patients with moderate
Alzheimer’s disease (MMSE,20) and patients with mild Alzheimer’s disease (MMSE.=20) (panel B). The Y axes show the standardized
differences in lipid level: lipid levels were standardized to a mean of 0 and standard deviation of 1 across all samples before ranking and plotting. For
Alzheimer’s disease versus controls, P=1.6610
29 for sphingomyelins and P=0.00034 for ceramides (Wilcoxon signed rank test two sided on means
over the standardized data). For moderate versus mild Alzheimer’s disease, P=7.1610
28 for sphingomyelins and P=0.10 for ceramides.
doi:10.1371/journal.pone.0021643.g006
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levels of additional 6 sphingomyelin species are different between
AD and control groups at the p,0.1 level.
Mass levels of ceramide species in AD patients
In contrast to the reduction of sphingomyelin mass levels in
plasma of AD patients, we identified significantly increased mass
levels of 2 ceramide species (N16:0 and N21:0) (p,0.05) (see
Figure 4 below for distribution in individual patients between the
groups) and of other 5 species at the p,0.1 level in plasma of AD
patients in comparison to those of controls (Table 4). The rest of
the ceramide species were not significantly different between the
AD and control groups.
Ratios of ceramide to sphingomyelin species containing
identical fatty acyl chain
We computed ratios of ceramides to sphingomyelins, and then
used Wilcoxon rank sum tests to compare ratios between groups.
Numerous ratios differed significantly between the groups. The
ratios appeared to discriminate AD versus controls more robustly
than the differences seen with individual ceramide or sphingomy-
elin species (Table 5 and Figure 5 compared to Tables 2 and 3 and
Figures 3 and 4, respectively).
Sphingolipidome Alterations in Mild versus Moderate AD
The rank of the mean mass levels of all determined individual
SM and ceramide species indicates that the reduction of SM mass
levels and the increases in ceramide mass levels in AD plasma
samples are essentially in uniformity, with only a few exceptions
(two SM species and four ceramide species which are located at
the end of small changes) (Figure 6A).
Identical data analysis was performed to compare the mass
levels of these classes in mild AD patients (MMSE.=20) and in
moderate AD patients (MMSE,20) relative to the normal
controls, respectively. We found that the changes of both lipid
classes in either mild AD patients (p=2.3e-10 for SM and
p=0.021 for ceramides) or moderate AD patients (p=0.0066 for
SM and p=0.00013 for ceramides) relative to the controls are
significant (Figure 6B).
Mass levels of many sphingomyelin and ceramide species were
correlated with AD severity (Figure 7). For example, the rank of
AD severity (i.e., MMSE) was significantly correlated with the rank
of the altered mass levels of both N20:2 SM and OH-N25:0
ceramide (p values of 0.00328 and 0.00379, respectively).
Exploratory analyses of the effects of statins on mass
levels of SM and ceramides
Concomitant statin use is common in the elderly and may
confound the identification of the altered plasma SM and
ceramide profiles in AD. Our data suggests that statins
significantly lowered levels of both SM and ceramides in both
AD and controls (Figure 8). However, this effect does not
significantly affect our main finding of lower SM mass levels and
higher ceramide contents in AD patients relative to the controls
(Figure 8).
Effect of APOE4 genotype on the mass levels of plasma
lipidome
In exploratory analyses, there was no significant relationship
between APOE genotypes and the altered SM and ceramide
profiles. However, mass levels of a few plasma lipid classes
including SM, phosphatidylcholine, and cholesterol were signifi-
cantly lower in AD patients carrying APOE4 allele(s) than those
carrying other APOE isoforms, but such mass differences were not
present in normal controls (Figure 9).
Discussion
This is the first prospective study, to our knowledge, to utilize a
highly efficient multidimensional shotgun lipidomic platform to
examine over 800 lipid species in plasma of a well characterized
sample of AD and control subjects. The median MMSE of our AD
was 21 which is in the mild range, but we also included patients
Figure 7. Correlation of the rank of the changed mean mass
levels of sphingomyelin and ceramide species with the rank of
AD severity. P values are based on Pearson’s product moment
correlation coefficient between the ranks as plotted. The lines represent
linear regressions of the ranks of the MMSE scores against the ranks of
the lipids.
doi:10.1371/journal.pone.0021643.g007
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usually in outpatient clinics. There were several key findings that
emerged: First, we demonstrated significant reductions of
sphingomyelin mass and significant increases in ceramide content
in plasma of AD patients. Second we demonstrated that the rank
order of these opposing changes are essentially species specific and
uniform. Third, we showed that ratios of SM and ceramide species
with identical fatty acyl chains results in more robust discrimina-
tion than either metabolite alone. Fourth, we showed that our
findings are seen both in mild and moderate stages of AD with
some metabolites also showing correlations with cognitive
performance. In addition, although the numbers of samples
genotyped are small our data suggest ApoE4 genotype specific
metabolite differences in AD. The small sample size also made it
Figure 8. Lower sphingomyelins and higher ceramides in Alzheimer’s patients are independent of statin use. Panel A shows the
differences in sphingomyelin and ceramide mass levels between AD patients and controls who were taking statins. For this comparison, P=7610
24
for sphingomyelins and P=0.00054 for ceramides (Wilcoxon signed rank test). Panel B shows the differences of sphingomyelin and ceramide mass
levels between AD patients and controls who were not taking statins. For this comparison, P=3.2610
28 for sphingomyelins and P=0.0056 for
ceramides (Wilcoxon signed rank test).
doi:10.1371/journal.pone.0021643.g008
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the stage of disease development. However, the analyses reported
in this paper were meant to be hypotheses generating and we hope
that these preliminary findings will stimulate further studies.
Concomitant use of statins did not confound our main findings
notably.
Previous studies have found that AD patients had higher levels
of ceramides in the middle frontal cortex [30] and white matter
[29]; levels peaked in early mild dementia (CDR=0.5) [29]. One
CSF study reported higher ceramide levels in moderate versus
mild or severe AD [48], while another examining brain tissue
reported that the gene expression patterns of enzymes participat-
ing in the sphingolipid metabolism pathway varied by AD severity
[49]. Elevated SM levels were found in the inferior parietal lobe of
AD patients, and had a strong positive correlation with the
number of amyloid-beta plaques [50]. In contrast, one study
reported lower SM levels in the middle frontal gyrus of AD
patients [30]. The conflicting results could be due to the stage of
the disease process studied. A recent study with human plasma has
found that serum SM and ceramides varied by time to onset of
memory impairment, i.e., the levels were higher pre-symptomat-
ically but lower at the time of impairment but also that higher
ceramide levels in prodromal AD was associated with greater
hippocampal atrophy [33]. Our findings are consistent with those
reported previously in the literature, but also extend them by
providing a deeper and broader characterization at the molecular
species levels and providing correlations with dementia severity
and genotype.
While the present results are intriguing, the exact biochemical
mechanism(s) leading to the reduction of these peripheral blood
lipids in people with memory loss still remains unknown. However,
investigators have speculated that changes in blood components
may be representative of structural and metabolic changes in the
brain [33,51]. SM species are important cellular membrane
constituents which are tightly associated with cholesterol in
construction, metabolism and transport, and which are enriched
in lipid rafts. SM species are metabolized into ceramides, an
important second messenger involving in regulation of cellular
differentiation, proliferation, and apoptosis [52]. Ceramides are
also intermediates linking inflammatory cytokines to insulin
resistance [53] and subclinical atherosclerosis [54,55]; all of which
are associated with AD pathogenesis.
To this end, we propose a neurochemical working model based
on our results (Figure 10). In the model, the increased ceramide
Figure 9. ApoE4 carriers with AD have significantly lower mass levels of sphingomyelin (panel A), phosphatidylcholine (panel B),
and cholesterol (panel C) (p=0.0238 for both lipid classes by Wilcoxon rank sum tests, two-sided).
doi:10.1371/journal.pone.0021643.g009
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which would involve either the increased levels or activities of
sphingomyelinase (SMase) or increased biosynthesis, which would
be largely associated with serine palmitoyltransferase. The former
is consistent with the lower mass levels of SM species as
determined in the current study. The latter is supported by our
metabolomic studies that saturated fatty acids and their derivatives
(e.g., monoacylglycerol) accumulate in CSF (unpublished data).
SM deficiency could lead to alterations in lipid raft formation,
thereby changing Glut 4 translocation and leading to glucose
accumulation in plasma as previously obtained [56,57]. This
model clearly is speculative and has many unanswered questions
that need further testing in subsequent studies.
There are some limitations to the study that need to be
considered. First is the issue of type 1 error. Although the sample
size of 52 participants is reasonable for a metabolomic analysis, the
number of comparisons raises the potential for spurious findings.
To control for this issue we restricted our comparisons to focused a
priori hypotheses of disturbances in lipid metabolism and we
employed relatively conservative p values for statistical signifi-
cance. Other sampling issues such as participation biases in our
groups, differences in age, diet, medical status and concomitant
medications, as well as genetic differences are also possible but
difficult to control within the logistics of recruiting a clinically
relevant sample. Regardless, replication of the results from this
study is important and should be conducted in more diverse and
larger clinical samples followed longitudinally over time. Addi-
tionally, this study included patients with diagnosed AD dementia
that were in the mild to moderate stages. Future studies would
benefit from the inclusion of patients with well-characterized mild
cognitive impairment, other dementing disorders as well as
asymptomatic patients with preclinical disease – i.e. other positive
biomarkers. Further, given the possible links between lipid
alterations and amyloidogeneis, it would be of great interest to
examine the relationship between lipidomics and amyloid
biomarkers, such as CSF or PET scans. It would also be of great
interest to analyze CSF and plasma lipidomics in the same subjects
to examine their relationships and relative efficacy as biomarkers.
Such studies will be essential to fully harness the potential of
lipidomics findings into biomarkers.
In summary, using shotgun lipidomics, we demonstrate
significant disruptions in the sphingolipidome in plasma obtained
from AD patients compared to normal controls. Our results
provide new insights into the relationship between lipid biochem-
istry and neuronal dysfunction in early AD and highlight the
promise of peripheral lipidomics for the identification of potential
new biomarkers. Deeper analysis of possible perturbations in other
lipid classes is underway.
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